Earnings Summary

Landos Biopharma Inc’s revenue jumped NaN% since last year same period to $0Mn in the Q4 2023. On a quarterly growth basis, Landos Biopharma Inc has generated NaN% jump in its revenue since last 3-months.

Landos Biopharma Inc’s net profit fell -57.71% since last year same period to $-6.12Mn in the Q4 2023. On a quarterly growth basis, Landos Biopharma Inc has generated -4.42% fall in its net profits since last 3-months.

Landos Biopharma Inc’s net profit margin jumped NaN% since last year same period to -Inf% in the Q4 2023. On a quarterly growth basis, Landos Biopharma Inc has generated NaN% jump in its net profit margins since last 3-months.

Landos Biopharma Inc’s earning per share (EPS) estimates for the current quarter stand at -1 - a -9.89% fall from last quarter’s estimates.

Landos Biopharma Inc’s earning per share (EPS) estimates for the current year stand at -1.

Landos Biopharma Inc’s earning per share (EPS) fell -661.54% since last year same period to -0.99 in the Q4 2023. This indicates that the Landos Biopharma Inc has generated -661.54% annual rate of fall in its earning per share (EPS) in the last 4 quarters.

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Landos Biopharma Inc’s return on assets (ROA) stands at -0.34.

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Landos Biopharma Inc’s return on equity (ROE) stands at -0.62.